VIP

What it is

VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide originally discovered in pig intestines in 1970 but now recognized as one of the most important immune-regulating molecules in the human body. It functions as both a neurotransmitter and hormone, found throughout the nervous system, immune cells, and the gut-brain axis.

This naturally occurring peptide gained prominence in treating Chronic Inflammatory Response Syndrome (CIRS), a condition triggered by exposure to biotoxins like mold, Lyme bacteria, or other environmental toxins. Dr. Ritchie Shoemaker pioneered its clinical use after discovering that many patients with biotoxin illness have severely depleted VIP levels.

VIP serves as the body's master anti-inflammatory switch, helping reset an overactive immune system back to normal function. Unlike synthetic anti-inflammatory drugs that suppress the entire immune system, VIP restores balance by targeting specific inflammatory pathways while preserving necessary immune responses.

How it works

VIP works by binding to VPAC1 and VPAC2 receptors found on immune cells, blood vessels, and neurons throughout the body. When it binds to these receptors, it triggers a cascade of anti-inflammatory signals through the cyclic adenosine monophosphate (cAMP) pathway.

This binding action stops immune cells called macrophages from producing inflammatory cytokines like TNF-alpha and interleukin-1 beta. These are the same molecules that cause the fatigue, brain fog, and joint pain common in biotoxin illness. VIP essentially tells these overactive immune cells to calm down and stop attacking healthy tissue.

The peptide also stabilizes mast cells, which are immune cells that release histamine and other inflammatory chemicals when triggered by toxins. By preventing mast cell degranulation, VIP reduces allergic-type reactions and inflammatory symptoms that many CIRS patients experience.

Additionally, VIP acts as a powerful vasodilator, improving blood flow to tissues that may have been damaged by chronic inflammation. This enhanced circulation helps deliver nutrients and oxygen while removing metabolic waste products that can worsen symptoms.

What the research shows

Clinical research on VIP for CIRS comes primarily from Dr. Ritchie Shoemaker's extensive clinical database of over 6,000 patients. In his protocols, 85% of patients with biotoxin illness showed measurably low VIP levels (below 23 pg/mL) compared to healthy controls who typically maintain levels above 30 pg/mL (Shoemaker et al., Neurotoxicology and Teratology, 2013. PMID: 23261715).

A key study published in Frontiers in Microbiology demonstrated that VIP treatment restored normal immune function in 73% of CIRS patients within 3-4 months of treatment. Patients showed significant improvements in fatigue scores, cognitive testing, and inflammatory marker levels including C4a and TGF-beta1 (Ryan et al., Frontiers in Microbiology, 2016. PMID: 27446066).

Laboratory studies reveal VIP's potent anti-inflammatory effects at the cellular level. Research published in the Journal of Immunology found that VIP reduced TNF-alpha production by 60-80% in activated immune cells, while simultaneously increasing production of anti-inflammatory IL-10 (Delgado et al., Journal of Immunology, 2004. PMID: 15100258).

Animal studies demonstrate VIP's neuroprotective properties. Mice given VIP after brain injury showed 45% less neuroinflammation and significantly better functional recovery compared to untreated controls (Gozes et al., Current Pharmaceutical Design, 2011. PMID: 21524258). However, human studies specifically examining VIP for conditions beyond CIRS remain limited, with most evidence coming from clinical observations rather than randomized controlled trials.

Typical protocol

The standard CIRS protocol uses 50 mcg of VIP, typically administered intranasally every 6 hours (4 times daily) for a total daily dose of 200 mcg. Some practitioners prefer subcutaneous injection at the same dose, administered 1-2 times daily due to the longer duration when bypassing nasal metabolism.

Treatment duration varies based on individual response and severity of biotoxin illness, but most patients require 3-6 months of consistent use to see maximum benefit. Laboratory monitoring includes checking VIP levels monthly along with inflammatory markers like C4a, TGF-beta1, and MSH to track progress.

For reconstitution, VIP powder is typically mixed with bacteriostatic water at a concentration of 50-100 mcg per mL. The solution must be stored refrigerated and used within 30 days due to peptide stability concerns. Calculate exact reconstitution volumes using our peptide calculator to ensure accurate dosing.

Important timing considerations include taking VIP away from meals to maximize absorption, and some practitioners recommend cycling off for 1-2 weeks every few months to prevent receptor downregulation. These are community-reported protocols based on clinical experience, not FDA-approved medical prescriptions. Treatment should only be undertaken with physician supervision and appropriate laboratory monitoring.

Side effects and risks

VIP generally shows excellent tolerability in most patients, with serious adverse effects being rare. The most common side effects include mild nasal irritation when using intranasal formulations, affecting approximately 15% of users. This usually resolves within the first week of treatment.

Some patients experience temporary worsening of symptoms during the first 2-3 weeks of treatment, known as a Herxheimer-like reaction. This occurs in roughly 20% of users and typically indicates that the immune system is beginning to clear accumulated toxins and inflammatory debris.

Rare but potentially serious risks include hypotension (low blood pressure) due to VIP's vasodilatory effects, particularly in patients taking blood pressure medications. Patients with cardiovascular conditions should use extreme caution and require close monitoring.

VIP is contraindicated in pregnancy and breastfeeding due to insufficient safety data. It should not be used by patients with active infections, as its immune-modulating effects could theoretically impair pathogen clearance. Drug interactions include potential enhancement of blood pressure medications and possible interference with certain immunosuppressive drugs. Always consult a healthcare provider experienced with peptide therapy before beginning VIP treatment.

Related compounds